Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 1, 1997, Pages 36-39

  Pienta, Kenneth J ^a   Esper, Peggy S ^a   Zwas, Fred ^b   Krzeminski, Reene ^b   Flaherty, Lawrence E ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

Chemoprevention; Clinical trials; Prostate cancer; Retinoids; Vitamin A

Indexed keywords

FENRETINIDE; RETINOL; RETINOL DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER INHIBITION; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERABILITY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PROSTATE ADENOCARCINOMA; TRANSCRIPTION REGULATION;

ADENOCARCINOMA; AGED; ANTICARCINOGENIC AGENTS; BIOPSY; FEASIBILITY STUDIES; FENRETINIDE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 0031031930     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199702000-00008     Document Type: Article

References (8)

1. Goodman GE. Phase II trial of retinol in patients with advanced cancer. Cancer Treatment Rep 1986;70:1023-4.
2. Semour L, Romney MD, Dwyer A. Chemoprevention of cervix cancer: phase I-II, a feasibility study involving the topical vaginal administration of retinol acetate gel. Gynecol Oncol 1986;20:109-19.
3. Pollard M, Luckert PH, Sporn MB. Prevention of primary prostate cancer by N-4-hydroxyphenyl retinamide. Cancer Res 1991;51:3610-1.
4. Rotmensz N, De Palo G, Formelli F, et al. Long-term tolerability of fenretinide (4HPR) in breast cancer patients. Eur J Cancel 991;27:1127-31.
5. Lippman SM, Kessler JF, Meyskens FL. Retinoids as preventive and therapeutic anticancer agents (part I). Cancer Treat Rep 1987;71:391-405.
6. Peng YM, Dalton WS, Alberts DS, Xu JJ, Lim H, Meyskens FL. Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. Int J Cancer 1989;43:22-6.
7. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA 1995;45:8-30.
8. Brawn PN, Speights VO, Kuhl D, et al. Prostate specific antigen levels from completely sectioned, clinically benign, whole prostates. Cancer 1991;68:1592-9.